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Summary 
Flightless (Flii) is upregulated in response to wounding and has been shown to 
function in wound closure and scarring. In macrophages intracellular Flii negatively 
modulates TLR signalling and dampens cytokine production. We now show that Flii 
is constitutively secreted from macrophages and fibroblasts and is present in human 
plasma. Secretion from fibroblasts is upregulated in response to scratch wounding and 
LPS-activated macrophages also temporally upregulate their secretion of Flii. Using 
siRNA, wild-type and mutant proteins we show that Flii is secreted via a late 
endosomal/lysosomal pathway that is regulated by Rab7 and Stx11. Flii contains 11 
leucine rich repeat (LRR) domains in its N-terminus that have nearly 50% similarity 
to those in the extracellular pathogen binding portion of Toll-like receptor 4 (TLR4). 
We show secreted Flii can also bind LPS and has the ability to alter macrophage 
activation. LPS activation of macrophages in Flii depleted conditioned media leads to 
enhanced macrophage activation and increased TNF secretion compared to cells 
activated in the presence of Flii. These results show secreted Flii binds to LPS and in 
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doing so alters macrophage activation and cytokine secretion, suggesting that like the 
intracellular pool of Flii, secreted Flii also has the ability to alter inflammation. 
 
Introduction 
Flightless (Flii) is a member of the gelsolin superfamily of proteins and 
contains six gelsolin domains in its C-terminal end. Like other members of this family 
it binds actin and has F-actin severing activity via these domains (Goshima et al., 
1999; Liu and Yin, 1998). As may be expected for an actin-remodelling protein, Flii 
regulates fibroblast and keratinocyte migration both in vitro and in vivo (Cowin et al., 
2007). Many actin-binding proteins, including gelsolin family members, also have a 
role within the nucleus and Flii is no exception (Lee et al., 2004; Lee and Stallcup, 
2006; Liu and Yin, 1998). Mice that lack other members of the gelsolin family are 
viable and fertile while the homozygous knockout of Flii in mice is embryonically 
lethal (Campbell et al., 2002). These results suggest other essential roles for Flii and 
its functions have now expanded well beyond the gelsolin-like actin remodelling and 
transcriptional regulator role found with other members of the family (Dai et al., 
2009; Hayashi et al., 2010; Li et al., 2008; Wang et al., 2006).  
Intracellular Flii is now emerging as an important negative regulator of 
inflammation (Dai et al., 2009; Li et al., 2008; Wang et al., 2006). Stimulation of 
Toll-Like Receptor (TLR) signalling pathways ultimately lead to transcription factor 
activation and the generation of cytokine and chemokine production (Kumar et al., 
2011). This pathway is tightly regulated to prevent excessive and/or stimulation and 
increased signalling. Flii is a negative regulator of this pathway (Dai et al., 2009; 
Wang et al., 2006). Through its interaction with nucleoredoxin and MyD88 in 
macrophages Flii inhibits the binding of MyD88 to TLR4 resulting in reduced 
activation of NF-kB leading to diminished cytokine secretion (Dai et al., 2009; Wang 
et al., 2006). Flii has also been shown to inhibit cytokine secretion by other 
mechanisms (Li et al., 2008). Flii also binds to the proinflammatory caspases 1 and 11 
and in doing so has been found to negatively regulate caspase-1 mediated interleukin-
1β maturation and secretion (Li et al., 2008). Thus, Flii has the ability to dampen 
inflammation through a number of intracellular mechanisms.  
The actions of Flii described to date involve intracellular Flii, however, results 
suggest that Flii may also be secreted (Cowin et al., 2007). We now show that Flii is 
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secreted through a non-classical late endosome/lysosome-mediated pathway by at 
least two of the major cell types found in wounds: fibroblasts and macrophages. 
Secretion of Flii from fibroblasts is upregulated in response to wounding and a similar 
upregulation in secretion also occurs from LPS-activated macrophages. The N-
terminal sequence of Flii shows nearly 50% similarity to the extracellular Leucine-
Rich Repeat (LRR) domain of TLR4 (Wang et al., 2006). The LRR regions of TLRs 
play a key role in innate immunity by recognising structurally conserved molecules 
derived from microbes, with lipopolysaccharide (LPS) from Gram-negative bacteria 
being the archetypical TLR4 (Erridge, 2010; Kumar et al., 2011; Piccinini and 
Midwood, 2010). We show that secreted Flii, with its TLR4 like N-terminus can bind 
LPS and negatively regulate cytokine production from macrophages.  
 
Results 
Flii secretion is both constitutive and regulated.  
To test whether Flii can be secreted from fibroblasts, extracts and media from a 
confluent layer of NIH3T3 fibroblasts (unwounded) were collected over an 8-hour 
time course. Samples were loaded equally on a SDS-PAGE gel (Fig 1A and 
supplementary material Fig. S1) and immunoblotted for Flii and actin (Fig. 1A). The 
anti-Flii antibody detected a band around 145 kDa both in the whole cell lysates and 
in media (Fig. 1). Little to no change in intracellular Flii levels were seen over the 
time course (Fig. 1A), however the level of Flii in the media increased with time 
suggesting it is constitutively secreted from fibroblasts (Fig. 1A,B). We have 
previously shown that Flii is upregulated in mouse skin wound tissue in response to 
injury (Adams et al., 2009; Cowin et al., 2007). Since Flii levels increase in the 
wounds of mice, scratch wounds were created in a confluent layer of NIH3T3 
fibroblasts to determine whether scratch wounding these cells could alter Flii 
secretion. Cell extracts and media were also collected from these cells over the same 
8-hour time course and immunoblotted for Flii and actin (Fig. 1A,B). The level of 
intracellular Flii was similar to that found in unscratched fibroblasts (Fig. 1A). 
However, the amount of secreted Flii was increased by 1.5 to 2.5 fold upon scratch 
wounding compared to media from unwounded cells incubated for the same time 
period suggesting its secretion is upregulated upon wounding (Fig. 1A,B). 
Immunoblotting of the same media samples for the cytosolic enzyme glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) and for actin showed that the presence of Flii 
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in the media is not due to general cytosol leakage or cell disruption (Fig. 1A). The 
activity of a known secreted lysosomal enzyme, beta-hexosaminidase, was also 
analysed in media from control and scratched fibroblasts (Fig. 1C). While the level of 
enzyme activity increased over the 8-hour time course no significant differences were 
seen between the amount of beta-hexosaminidase activity in the media from scratched 
and control fibroblasts (Fig. 1C). This data shows that beta-hexosaminidase is also 
secreted from these cells; however, unlike Flii its level of secretion is not significantly 
increase upon wounding. We next looked at the level of Flii secreted from cells over 
the 8-hour scratch wounded period (Fig. 1D). The levels of Flii secreted into the 
media 6 hours after scratching wound is equivalent to approximately 3% of the total 
intracellular pool of Flii (Fig. 1D). Thus, Flii is constitutively secreted by fibroblasts 
and its secretion can be upregulated in response to scratch wounding.  
Immunoblotting of skin and plasma from healthy volunteers for Flii, the 
plasma marker albumin and the cellular marker tubulin showed that Flii is present in 
plasma as well as the skin (Fig. 1E). Flii has been found in macrophages where it can 
regulate TLR signalling and cytokine secretion (Dai et al., 2009; Hayashi et al., 2010; 
Wang et al., 2006). Monocyte/macrophages are present in high numbers both in 
wounds and plasma and so whether Flii could also be secreted from macrophages was 
next tested. Extracts from RAW264.7 macrophages were first immunoblotted 
alongside equal protein levels of NIH3T3 fibroblast extracts (Fig. 1F). Similar 
intracellular levels of Flii were seen in both cell types (Fig. 1F). To test whether Flii is 
also secreted by macrophages and whether this secretion is altered when macrophages 
are activated and secreting cytokines, RAW264.7 macrophages were stimulated with 
the bacterial cell wall component lipopolysaccharide (LPS) over a 6-hour time course. 
Cell extracts were immunoblotted for Flii, actin and the proinflammatory cytokine 
TNF (Fig. 1G,H). Thirty minutes post LPS stimulation we saw the characteristic 
upregulation of intracellular TNF protein levels, which peaked around 3 hours post 
stimulation, while the total levels of intracellular Flii appeared unaltered over the 
same time course (Fig. 1G) (Murray et al., 2005b). Immunoblotting of conditioned 
media collected from the same cells showed TNF secretion started 30 minutes post 
LPS stimulation and gradually increased (Fig. 1G,H). Moreover, Flii was also 
secreted by macrophages and in LPS-activated macrophages secretion peaked at 
around 30 minutes post-stimulation (Fig. 1G,H). These results together suggest Flii is 
constitutively secreted by both fibroblasts and macrophages and that Flii secretion can 
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be upregulated from fibroblasts in response to scratch wounding and in macrophages 
in response to LPS-activation.  
 
Flightless is located in the nucleus, cytosol and in late endosomes/lysosomes. 
Since Flii has previously been found in both the nucleus and cytoplasm of Swiss 3T3 
fibroblasts its location in unwounded NIH3T3 cells and scratch wounded fibroblasts 
was next analysed (Davy et al., 2001). Cell extracts from unwounded and scratch 
wounded confluent NIH3T3 fibroblasts were separated into nuclear and post-nuclear 
fractions (Fig. 2A). Equal protein was loaded and probed for Flii, the cytoplasmic 
marker protein tubulin and the nuclear marker protein HDAC1 (Fig 2A). Flii was 
predominantly located in the post-nuclear fraction in NIH3T3 fibroblasts and its 
location did not significantly alter upon wounding (Fig. 2A). RAW264.7 
macrophages were incubated in the presence or absence of LPS for 3 hours and 
extracts were separated into nuclear and post-nuclear fractions to determine its 
location. Fractions were immunoblotted for Flii, the cytoplasmic marker protein 
tubulin, the nuclear marker protein nucleoporin and the cytokine TNF (Fig. 2B). The 
majority of Flii was located in the post-nuclear fraction that contains membranes and 
cytosol in macrophages regardless of their activation state (Fig. 2B). Post-nuclear 
fractions from both NIH3T3 cells and RAW264.7 cells were next separated into 
membrane and cytosol using a high-speed centrifugation step. Membrane and cytosol 
fractions were probed for Flii, the trans-membrane protein LAMP1 and the 
cytoplasmic protein β-actin (Fig. 2C). In both fibroblasts and macrophages Flii is 
located both in the cytosol and the membrane fractions (Fig. 2C).  
Immunostaining of Flii in both fibroblasts and macrophages revealed that Flii 
was located in the cytosol as well as in large endosomes located in the perinuclear 
region and throughout the cytoplasm (Fig. 3A,B). Some Flii could be detected in the 
nuclei of fibroblasts but its levels differed depending on the individual cell (Fig. 3A). 
Primary mouse fibroblasts were co-immunostained for Flii along with the late 
endosome/lysosome marker VAMP7 or cathepsin D, a late endosome/lysosomal 
protease that is also secreted by some cell types.  Flii is located in the nucleus, cytosol 
and in late endosomes/lysosomes in fibroblasts (Fig. 4A). Immunostaining of 
RAW264.7 macrophages for Flii in combination with the late endosome/lysosome 
membrane proteins LAMP1 and VAMP7, as well as cathepsin D, showed these 
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proteins colocalised in macrophages (Fig. 3B). Thus, Flii is located in late 
endosomes/lysosomes with cathepsin D in fibroblasts as well as macrophages and is 
potentially trafficked to the surface via late endosomes/lysosomes.  
 
Flii is secreted via a late endosome/lysosomal pathway 
We next looked to see how Flii might be being secreted. Two major types of routes 
for secretion exist, classical and non-classical. In the classical pathway proteins are 
trafficked from the endoplasmic reticulum (ER) via the Golgi complex en route to the 
cell surface (Bonifacino and Glick, 2004). In this pathway secretory proteins in this 
pathway contain amino-terminal or internal signal peptides that direct their sorting to 
the endoplasmic reticulum (ER). Flii’s amino acid sequence was analysed using 
SignalP 3.0 (www.cbs.dtu.dk/services/SignalP) and the results established that Flii 
lacks a secretory signal peptide (probability = 0.014). This suggested that Flii might 
not be secreted via the classical pathway. To confirm this, Flii was co-immunostained 
in RAW264.7 macrophages with the Golgi protein VAMP4, as well as with the 
known classical secretory pathway trafficked cytokine TNF (Murray et al., 2005a; 
Murray et al., 2005b). Flii did not colocate with the Golgi associated SNARE protein 
VAMP4 or the cytokine TNF (Fig. 2C). Brefeldin A (BFA) has been shown to cause 
disruption of the Golgi and prevent proteins trafficking from the ER to the Golgi 
through the classical pathway (Fujiwara et al., 1988). To confirm that Flii is not 
secreted via the classical pathway, RAW264.7 macrophages were incubated in the 
presence or absence of BFA (5ng/ml) for 60 min with LPS (100 ng/ml) for the last 30 
min. Fixed cells, immunostained for the Golgi marker protein GM130, showed that in 
the presence of BFA the Golgi was disrupted as expected (Fig. 4B). Immunoblotting 
of extracts from these cells showed that the levels of Flii inside the cell and secreted 
in the media were not altered in the presence of BFA (Fig. 4C) confirming that Flii is 
not secreted via the classical pathway.  
The delivery of cargo to the cell surface via late endosomes/lysosomes is a 
known non-classical pathway of secretion and the presence of Flii in late 
endosome/lysosomes suggest that Flii may be secreted via this same pathway (Nickel, 
2003). The small G-protein Rab7 regulates traffic through the late endosome (Bucci et 
al., 2000; Vanlandingham and Ceresa, 2009). To determine whether Flii is indeed 
trafficked through the late endosome on route to the cell surface RAW264.7 
macrophages were transiently transfected with GFP, GFP-Rab7 or a GFP-tagged 
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dominant negative form of Rab7 (GFP-Rab7T22N) known to inhibit traffic through 
this organelle (Bucci et al., 2000). Extracts from these macrophages were 
immunoblotted for Flii, cathepsin D, GFP and actin (Fig. 5A). The intracellular levels 
of both Flii and the mature form of cathepsin D were decreased by 25% and 21% 
respectively in cells transiently overexpressing GFP-tagged wild-type Rab7 as 
compared to cells expressing GFP alone (Fig 5A,B). This decrease in intracellular Flii 
in cells coincided with a 1.7-fold increase in Flii secreted into the media (Fig. 5A,B). 
Detection of cathepsin D in media by immunoblotting was obscured due to the large 
albumin band in the media so the same conditioned media was also analysed for the 
secreted lysosomal enzyme, beta-hexosaminidase (Fig. 5C). Similar to Flii, the level 
of secreted beta-hexosaminidase is increased (approximately 1.2 fold) in the 
conditioned media of cells transiently overexpressing GFP-Rab7 (Fig. 5C). 
Macrophages transiently transfected with the dominant negative form of Rab7 (GFP-
Rab7T22N) showed an increase (approximately 1.2 fold) in intracellular Flii and 
mature cathepsin D as compared to cells transfected with GFP alone (Fig. 5A,B). The 
increased intracellular Flii levels corresponded with a reduction in secreted Flii in the 
media by almost half compared with control GFP expressing cells suggesting 
secretion was blocked by expression of the dominant negative form of Rab7 (Fig 
5A,B). Similarly a reduction in beta-hexosaminidase secreted into the media was seen 
in conditioned media from cells expressing the dominant negative form of Rab7 (Fig. 
5C). These results together suggest that Flii is trafficked through a late 
endocytic/lysosomal compartment on route to the cell surface for secretion.  
 
Increasing fusion of a late endosome/lysosome compartment with the cell surface 
results in increased Flii secretion.  
We have recently shown that the loss of the SNARE protein Stx11 in macrophages 
leads to an increased fusion of a LAMP1-positive late endosomal/lysosomal 
compartment with the cell surface (Fig. 5D) (Offenhäuser et al., 2011). If Flii were 
trafficked via this same Stx11-regulated pathway then it would be expected that a 
reduction in Stx11 levels would deplete intracellular Flii pools while increasing the 
level of Flii secreted into the media. To test this, macrophages were treated with small 
interfering RNAs (siRNAs) to reduced the level of Stx11 (Fig. 6A,B). Cells treated 
with control or Stx11 siRNA were fixed, permeabilised and immunostained live for 
surface LAMP1 (Fig. 5D). As previously shown, surface levels of LAMP1 are greatly 
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increased on macrophages treated with Stx11 siRNA as compared to control treated 
cells, indicative of an increase in the fusion of LAMP1-positive organelles with the 
cell surface (Fig. 5D). Cell extracts from these macrophages were immunoblotted for 
Stx11, Flii, cathepsin D and actin and media from the same cells was immunoblotted 
for Flii (Fig. 5E). Compared to cells treated with control siRNA cells treated with 
siRNA to Stx11 showed a reduction in intracellular Flii and cathepsin D 
(approximately 50% and 20% respectively) and a concomitant increase (1.5 fold) in 
secreted Flii levels (Fig. 5E,F). An increase in the lysosomal enzyme beta-
hexosaminidase secreted into the media was also seen when cells were treated with 
Stx11 siRNA compared to control treated cells (Fig. 5G). These results together 
suggest that the pool of Flii located in a LAMP1-positive late endosome/lysosome 
compartment is trafficked to the cell surface and released into the extracellular milieu 
when this LAMP1-positive late endosome/lysosome-related compartment fuses with 
the cell surface. 
 
Secreted Flii binds to LPS and alters macrophage activation 
Eleven leucine-rich repeat (LRR) domains, located at the N-terminus between amino 
acids 57 to 362 in Flii, were identified using ScanProsite and InterPro Scan domain 
mapping tools (http://expasy.org/tools/) (Fig 6A). This LRR region shares 29% 
sequence identity and 42% similarity to the LRR domains found in the extracellular 
portion of TLR4 (Wang et al., 2006). The binding of the bacterial cell wall component 
LPS to this same domain in TLR4 leads to the signal transduction events that 
ultimately result in cytokine secretion (Bell et al., 2003). Thus, whether Flii, like 
TLR4, could also bind LPS was next tested. Conditioned media containing high levels 
of secreted Flii from scratch wounded NIH3T3 cells was incubated with LPS and 
antibodies to GFP, LPS or Flii bound to protein A-agarose. Co-immunoprecipitated 
proteins were immunoblotted for Flii and results confirmed the anti-Flii antibody was 
able to immunoprecipitate Flii as expected (Fig. 6B). Moreover, Flii from the 
conditioned media was immunoprecipitated with LPS (Fig. 6B). Addition of an 
antibody specific for the first LRR domain of Flii (Cowin et al., 2007), added to 
conditioned medium for 1 hour prior to the above immunoprecipitation experiment, 
inhibited the binding of Flii to LPS (Fig. 6C). These results suggest Flii might bind 
LPS via its LRR domain.  
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We next tested whether the binding of Flii to LPS could influence LPS-
activation of macrophages, looking at the effect of altering Flii levels on the 
downstream TNF production and secretion. Conditioned media, containing high 
levels of secreted Flii from scratch wounded NIH3T3 cells, was depleted of Flii using 
anti-Flii antibodies bound to protein A-agarose. Immunoblotting showed Flii levels in 
the medium were greatly depleted (Fig. 6D). Macrophages grown on coverslips were 
incubated in conditioned media containing high levels of Flii or in the Flii depleted 
media and stimulated with LPS for 3 hours then fixed, permeabilised and stained for 
TNF and F-actin. Both the level and the number of cells expressing TNF were greatly 
reduced in the presence of high levels of Flii, suggesting Flii may inhibit LPS 
activation of macrophages (Fig. 6E). To confirm this, extracts from LPS stimulated 
macrophages incubated in conditioned media containing Flii or in Flii depleted media 
were immunoblotted for TNF and actin. In the presence of high levels of Flii the total 
TNF levels were reduced by approximately 30% compared to cells stimulated in Flii 
depleted media (Fig. 6F,H). A 40% reduction in secreted TNF was seen when cells 
were stimulated with LPS in the presence of high levels of Flii (Fig. 6G,H). These 
results suggest that secreted Flii may sequester LPS, preventing it from activating 
macrophages.  
 
Discussion 
Intracellular Flii has been found to be an important negative regulator of 
inflammation (Dai et al., 2009; Li et al., 2008; Wang et al., 2006). We now show that 
Flii is also secreted and the secreted form can also regulate inflammation. Flii is 
constitutively secreted by both fibroblasts and macrophages and can be found in 
plasma samples from healthy volunteers. Secretion of Flii can be upregulated by 
either scratch wounding fibroblasts or LPS stimulating macrophages.  Flii is secreted 
via a late endocytic/lysosomal compartment and both Rab7 and the SNARE Stx11 
regulate this trafficking pathway in macrophages. Flii also locates to the same 
compartment in fibroblasts, suggesting Flii is secreted via a similar pathway in both 
cell types. Inhibition of this trafficking pathway results in increased intracellular Flii 
and a reduction in secretion, while increasing fusion of late endosomes/lysosomes 
increases Flii secretion. Once secreted Flii can bind to LPS and this binding can be 
inhibited with an antibody specific for the LRR domains at the N-terminus of Flii. 
Macrophages stimulated with LPS in the presence of media depleted of Flii synthesise 
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and secrete more TNF, suggesting secreted Flii may act to sequester LPS and alter 
cytokine secretion during an inflammatory response. 
Biochemical and localisation studies in NIH3T3 fibroblasts revealed that Flii 
is located in the nucleus, cytosol and in late endosomes/lysosomes. In RAW264.7 
macrophages the majority of Flii is located in the cytosol and in late 
endosomes/lysosomes. Flii has previously been found in the nucleus, cytosol and to 
be associated with the cytoskeleton in Swiss 3T3 cells (Davy et al., 2001). The slight 
difference in localisation may reflect the different cell types and perhaps the functions 
of Flii in these cells. Flii has been found to play a number of different roles in cells 
(Cowin et al., 2007; Davy et al., 2001; Kopecki and Cowin, 2008; Wang et al., 2006). 
In macrophages the cytosolic pool of Flii has been found to bind to MyD88 and 
prevent it’s binding the cytoplasmic tail of TLR4 (Wang et al., 2006). Flii also binds 
to caspase-1 in macrophages where it can inhibit the maturation of interleukin-1β 
maturation and leading to a reduction in its secretion (Li et al., 2008). Interestingly 
pro-interleukin-1β and caspase-1 have both been shown to be found in late 
endosomes with Cathepsin D and to be secreted from this compartment (Andrei et al., 
1999; Eder, 2009). 
Lysosomes or lysosome-related organelles have been found to perform a range 
of functions, some common to all cell types, such as degradation, whilst others are 
more specialised and tend to involve fusion of this organelle with the cell surface to 
release its contents (Holt et al., 2006; Luzio et al., 2007). We have used Rab and 
SNARE proteins, located on specific membranes that regulate transport at distinct 
sites in the late endosome/lysosome pathway, to show Flii is secreted from this 
compartment (Stow et al., 2006; Zerial and McBride, 2001). Rab7 is located on late 
endosomes, where it regulates traffic to lysosomes (Bucci et al., 2000; 
Vanlandingham and Ceresa, 2009). Similarly the SNARE protein Stx11 is located on 
late endosomes and lysosomes and regulates traffic between these organelles and the 
cell surface (Offenhäuser et al., 2011). Loss of either Rab7 or Stx11 results in 
enlarged endosomes and loss of Stx11 leads to increased fusion of this late 
endosocytic/lysomal compartment with the cell surface (Offenhäuser et al., 2011; 
Vanlandingham and Ceresa, 2009). We now show that Rab7 and Stx11 regulate Flii 
secretion from a late endocytic/lysosomal compartment in macrophages. Similar 
results were seen for cathepsin D, which is known to be secreted via a late 
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endocytic/lysosomal compartment (Gardella et al., 2001). 
Lysosomal secretion can be either from distinct subsets of lysosome related 
organelles, for example melanosomes, or from organelles that are indistinguishable 
from lysosomes themselves (Holt et al., 2006; Luzio et al., 2007).  Secretion from 
these organelles is often switched on by external stimuli, such as the recognition of a 
foreign antigen (Holt et al., 2006; Luzio et al., 2007). Our results suggest that in both 
fibroblasts and macrophages secretion of Flii from a late endosome/lysosome 
compartment is constitutive and can be upregulated in response to specific external 
stimuli. In response to scratch wounding fibroblasts secrete up to 2.5 times more Flii 
that unwounded cells, whilst in macrophages LPS activation leads to a temporal 
increase in secreted Flii 30 minutes after activation. No increase in intracellular Flii 
was seen after scratch wounding to match the increase in secretion, however the level 
of Flii secreted is very low (3% over 6 hours) in comparison to the total cellular 
levels. These results suggest that secretion from this compartment may be continual 
but can be amplified in response to external stimuli. It is currently unclear how Flii 
enters the late endosomal/lysosomal compartment but future studies will address this 
question. 
Mice with increased levels of Flii have impaired wound healing compared to 
control mice, while mice with low levels of Flii have significantly improved wound 
healing responses (Cowin et al., 2007). However, Flii is upregulated in tissue in 
response to injury in mice and we now show fibroblasts increase secretion of Flii in 
response to wounding (Adams et al., 2009; Cowin et al., 2007). The upregulation of 
Flii in response to injury seems counterproductive since increasing the levels of Flii 
leads to reduced cell migration, impaired healing and increased scar formation. The 
results shown here suggest the answer may lie in part in Flii’s ability to also alter the 
inflammatory response. Whilst mounting a successful immune response is important 
to clear an infection, a hyper-activated immune response leads to overproduction of 
tissue damaging cytokines, which could potentially be detrimental to the wound, as 
well as systemically where it can lead to sepsis (Murphy et al., 2004). Intracellular 
Flii has previously been shown to negatively regulate cytokine secretion by inhibiting 
MyD88 binding to TLR4 and effectively acts to the reduce signalling for cytokine 
production and dampen the inflammatory response (Dai et al., 2009; Wang et al., 
2006). Our results now suggest that Flii is also secreted and that extracellular Flii can 
also alter cytokine secretion by binding to LPS. The binding of Flii to LPS and the 
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timing of Flii secretion suggest that Flii may act as a scavenger to help mop up excess 
LPS and prevent hyper-activation of the immune system. These results suggest that 
the upregulation of Flii in wounds might serve to alter inflammation in the wound and 
prevent excess stimulation of cytokine production.  
The related protein gelsolin is also secreted and the extracellular form has 
been shown to dampen the immune response by binding to LPS and lipoteichoic acid 
(LTA), released from the outer walls of Gram-negative and Gram-positive bacteria 
respectively (Bucki et al., 2008; Bucki et al., 2005). Thus, it has been proposed that 
extracellular gelsolin may act as an extracellular scavenger for these bacterial cell 
wall components (Bucki et al., 2008). The region in gelsolin that binds to LPS is not 
present in Flii (data not shown); however, Flii does have an LRR domain at it N-
terminus, not present in other gelsolin family members (Kopecki and Cowin, 2008; 
Mintzer et al., 2006). The LRR domain in Flii shares 29% sequence identity and 42% 
similarity to the LRR domain in TLR4 (Wang et al., 2006). The LRR domain of TLRs 
is located on the extracellular side of the plasma membrane and has been shown to be 
involved in the binding of pathogen-associated molecular patterns (PAMPs) from a 
range of pathogens, including LPS, as well as damage-associated molecular patterns 
(DAMPs) found in some host molecules released upon injury (Bell et al., 2003; 
Erridge, 2010; Kumar et al., 2011). The binding of Flii to LPS and the timing of Flii 
secretion suggest that Flii may also act as a scavenger to help mop up excess LPS and 
prevent hyper-activation of the immune system. Since many proteins are released 
upon injury, a number of which also can activate TLR signalling, it remains to be seen 
whether secreted Flii can also act as a general scavenger protein that binds to the 
DAMPs in host intracellular proteins released upon injury (Erridge, 2010). In 
summary, Flii may be acting both in side and outside of the cell to dampen 
inflammation by negatively regulating intracellular TLR signalling as shown 
previously or as we now show by binding LPS and preventing activation of TLR 
signalling.  
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Materials and Methods 
Antibodies and reagents   
Antibodies specific for Vti1b, VAMP3, VAMP4 and VAMP7 were purchased from 
Synaptic Systems (Goettingen, Germany) and antibodies specific for cathepsin D and 
actin were purchased from Millipore (Kilsyth, Vic, Australia). Anti-mouse Flii (IgG 
Sc-21716), anti-rabbit Flii (IgG Sc-30046), anti-HDAC1 and anti-albumin antibodies 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-
GAPDH antibodies were purchased from Ambion (Austin, Texas, USA). Antibodies 
specific for LAMP1 were purchased from Southern Biotech (InVitro, Noble Park, 
Vic, Australia), while antibodies specific for nucleoporin and GM130 were purchased 
from BD Transduction Laboratories (North Ryde, NSW, Australia). Antibodies 
specific for TNF were purchased from Calbiochem (Merck, Kilsyth, Vic, Australia). 
Anti-LPS (E. coli) antibodies were purchased from Abcam (Sapphire Biosciences, 
Waterloo, NSW, Australia). Rabbit anti-GFP antibodies were purchased from 
Invitrogen (Mulgrave, Vic, Australia) and mouse anti-GFP antibodies were purchased 
from Roche (Castle Hill, NSW, Australia). HRP and CY3-tagged secondary 
antibodies were purchased from Jackson Laboratories (West Grove, PA, USA), while 
Alexa-488 and Alexa-647-tagged secondary antibodies and Alexa-488 phalloidin 
were purchased from Molecular Probes (Invitrogen, Mulgrave, Vic, Australia). Anti-
Flii LRR (IgM) antibodies made to amino acids 56-69 located in the first LRR 
domain of Flii as described previously (Adams et al., 2009). Anti-β-tubulin 
antibodies, LPS from Salmonella minosota Re595 and LPS from Escherichia coli J5 
(Rc mutant) (used in the immunoprecipitation experiments) and 4-nitrophenyl N-
acetyl-β-D-glucosaminide (20 μl) were purchased from Sigma (Sydney, NSW, 
Australia). Rabbit polyclonal anti-Stx11 antibodies were a kind gift from Prof Jenny 
Stow (University of Queensland, Australia) and have been described elsewhere 
(Offenhäuser et al., 2011). GFP-Rab7 and GFP-Rab7T22N were a kind gift from Prof 
Zerial (Max Planck Institute of Molecular Cell Biology and Genetics, Dresden).  
 
Preparation of human skin samples and plasma 
The collection of human skin and peripheral blood samples from patients undergoing 
abdominoplasty was approved by the Central Northern Adelaide Health Service 
Ethics of Human Research Committee. Peripheral blood collected in EDTA treated 
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blood collection tubes was centrifuged at 300 x g for 10 min at 4°C and the plasma 
transferred to a new tube. Samples were mixed with trichloroacetic acid at 1:10 
sample volume and centrifuged for 1.5 h at 6500 x g. Samples were resuspended in 
800 µl of -20°C acetone, incubated overnight at -20°C and centrifuged at 6500 x g at 
4°C for 10 minutes. The pellet was then resuspended in -20°C acetone, incubated at -
20°C for 30 minutes, recentrifuged, the acetone discarded and the pellet dried. The 
pellet was then resuspended in 1% SDS prior to separation on an SDS-PAGE gel.  
Human skin samples dissected into 0.5 mm x 0.5 mm pieces were lysed in RIPA 
buffer containing protease inhibitors (50 nM Tris, pH 7.2, containing 150 mM NaCl, 
2 mM EDTA, 1% TritonX-100, 1% nadeoxycholate, 1 mM Na3VO4, 1 mM NaF, 2 
mM Perfabloc and complete protease inhibitors (Roche, Castle Hill, NSW, 
Australia)). Samples were homogenised on ice using a Heidolph Diax 600 
homogenizer (Sigma, Sydney, NSW, Australia) at 22000 rpm for 1 min. 
Homogenised samples were incubated for 30 minutes at 4°C, then centrifuged at 
12000 rpm for 15 min and the supernatant collected for further analysis.  
 
Cell culture and transfection 
RAW264.7 murine macrophages were cultured and in some experiments the cells 
were activated for the times indicated with LPS (100 ng/ml) as described previously 
(Murray et al., 2005a). Primary fibroblasts from BALB/c mice were cultured as 
previously described (Kopecki et al., 2009). NIH3T3 fibroblasts were cultured 
according to the ATCC instructions in DMEM supplemented with 4 mM L-
glutamine, 1.5 g/L sodium bicarbonate 4.5 g/L glucose and 10 % FCS. Macrophages 
were transfected with cDNAs using Lipofectamine 2000 according to the 
manufacturer’s instructions (Invitrogen, Mulgrave, Vic, Australia). In some 
experiments RAW264.7 cells were incubated with 5 μg/ml Brefeldin A (BFA) for 30 
minutes and then LPS (100 ng/m) was added for a further 30 minutes.  For siRNA 
knockdown macrophages were transfected using Lipofectamine 2000 (Invitrogen, 
(Mulgrave, Vic, Australia), cultured for 24 hours, retransfected under the same 
conditions and then cultured for a further 24 hours prior to use as previously 
described (Veale et al., 2010).  
 
Cell fractionation 
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To separate nuclear and post nuclear fractions cells were detached from plates using 
0.25 % Trypsin/EDTA (Invitrogen, Mulgrave, Vic, Australia) for NIH3T3 cells or 0.5 
mM EDTA in PBS for RAW264.7 cells. The cells were washed once in ice cold PBS, 
resuspended in buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 
mM EGTA, 0.15% NP-40 and Complete protease inhibitors (Roche, Castle Hill, 
NSW, Australia) and incubated on ice for 15 minutes with occasional mixing. The 
lysed cells were centrifuged for 30 sec at 14,000 x g and the supernatant was the post 
nuclear fraction. The pellet containing intact nuclei was washed three times in Buffer 
A, resuspenend in Buffer B (20 mM HEPES, pH 7.9, 0.4 mM NaCl, 1 mM EDTA, 1 
mM EGTA, 0.5% NP-40 and Complete protease inhibitors (Roche, Castle Hill, NSW, 
Australia)), sonicated and centrifuged for 30 min at 14,000 x g and the supernatant is 
the nuclear fraction.  Samples (100 µg) were separated by SDS-PAGE.  Membranes 
and cytosol were prepared as previously described (Offenhäuser et al., 2011). The 
membrane volume was adjusted to the same as the cytosol and equal volumes loaded 
on SDS-PAGE gel.  
 
SDS-PAGE, immunoprecipitation, immunoblotting and immunofluorescence 
Cell extracts were prepared as previously described (Veale et al., 2010). Briefly, cells 
were washed three times with ice-cold PBS and lysed in Buffer C (10 mM Tris, pH 
7.4, containing 1 mM EDTA, 150 mM NaCl, 1% Triton X-100, and Complete 
protease inhibitors (Roche, Castle Hill, NSW, Australia)) by passage through a series 
of successively smaller needles. The supernatant was then collected after 
centrifugation for 30 min at 14,000 x g. Protein content in the supernatant was 
assayed using the BioRad protein assay kit according and 50 μg of protein subject to 
SDS-PAGE separation and immunoblotting. Densitometry was performed on bands 
within the linear range and fold changes in levels calculated from this data. For 
immunoprecipitation, the media was incubated with 5 μg of antibody bound to protein 
A-agaorose (Sigma, Sydney, NSW, Australia) for 2 h at 4 °C with constant mixing. 
The protein A-agarose was washed five times in excess Buffer C and the bound 
proteins were solubilised in SDS-PAGE sample buffer. Immunofluorescence staining 
was performed as described previously (Murray et al., 2005b). Surface staining of 
LAMP1 was performed on live cells on ice, then cells were fixed with 4% 
paraformaldehyde at room temperature as previously described (Offenhäuser et al., 
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2011). Confocal microscopy was performed using a Leica (North Ryde, NSW, 
Australia) TCS SP2 Confocal Microscope equipped with a 100X oil objective. 
Confocal images were pseudocolored where appropriate and overlaid for publication 
using Adobe Photoshop CS3. 
 
Measurement of beta-hexosaminidase activity 
Conditioned and unconditioned medium (20 μl) was incubated with 4.8 mM 4-
nitrophenyl N-acetyl-β-D-glucosaminide (20 μl) (Sigma-Aldrich) in citrate buffer 
(0.1 M, pH 4.5) at 37°C for 90 min. The reaction was halted by adding 150 μl 
carbonate buffer (0.1M, pH 9.0) and the absorption read at A415 (nm) and the activity 
in unconditioned media subtracted. 
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Figure legends 
 
Figure 1. Flii is expressed in human skin as well as being secreted into plasma. 
A) Scratch wounded and unwounded confluent monolayers of NIH3T3 fibroblasts 
were incubated over an 8-hour time course. Extracts and media from these cells were 
immunoblotted for Flii and the cytoplasmic proteins actin and GAPDH. No change in 
total intracellular Flii was seen, however, the level of Flii increased with time 
suggesting Flii is constitutively secreted and this secretion can be upregulated upon 
scratch wounding. WCL, whole cell lysate. B) Bar graph with SEM shows the 
increase in Flii in the media, calculated from three replicates of immunoblot data, 
over the time course (**, P<0.01; *, P<0.05). C) Media from scratch wounded and 
unwounded confluent monolayers of NIH3T3 fibroblasts incubated over an 8-hour 
time course was analysed for beta-hexaminidase activity. Bar graph with SEM (n=3) 
shows the activity of beta hexaminidase in the media increases over the time course 
but does not further increase upon scratch wounding. D) Scratch wounded confluent 
monolayers of NIH3T3 fibroblasts were incubated over an 6-hour time course. Media 
(1/40) and cell extracts (1/1300) from these cells were immunoblotted for Flii. E) 
Extracts from human skin and plasma were immunoblotted for Flii, β-tubulin and 
albumin. Flii is expressed in both skin and plasma. F) Extracts from NIH3T3 
fibroblasts and RAW264.7 macrophages were immunoblotted for Flii and Actin. Flii 
was present at similar levels in macrophages and fibroblasts. G) RAW264.7 
macrophages were stimulated with 100 ng/ml LPS over a 6 hour time course. Extracts 
and media were probed for Flii, TNF and actin.  
 
Figure 2. Flii is located in the nucleus and cytosol and is associated with a 
membrane fraction. A) Confluent NIH3T3 fibroblasts were scratch wounded and 
incubated for 0, 3 or 6 hours. Nuclear and cytoplasmic cell extracts prepared from 
these cells were immunoblotted for Flii, HDAC1 (nuclear marker) and tubulin 
(cytoplasmic marker). The majority of Flii was located in the cytoplasm and its 
translocation into the nucleus was not altered upon wounding. B) Nuclear and 
cytoplasmic cell extracts were prepared from RAW264.7 macrophages treated in the 
presence or absence of 100 ng/ml LPS for 3 hours and immunoblotted for Flii, the 
cytokine TNF, nucleoporin (nuclear marker) and β-tubulin (cytoplasmic marker). Flii 
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was predominantly found in the cytoplasm of macrophages. C) Membrane (M) and 
cytosol (C) prepared from RAW264.7 macrophages and NIH3T3 fibroblasts were 
immunoblotted for Flii, LAMP1 and actin. Flii is located both in the cytosol and in 
membrane fractions. 
 
Figure 3. Flii is located in the nucleus, cytoplasm and in late 
endosomes/lysosomes. A) Primary fibroblasts were immunostained for Flii and the 
late endosomal/lysosomal proteins cathepsin D or VAMP7. Flii localises to the 
nucleus, cytosol and late endosomes/lysosomes in fibroblasts. B) RAW264.7 
macrophages were immunostained for Flii with the late endosome/lysosome marker 
proteins LAMP1, VAMP7 and Cathepsin D (Cath D). Flii localises to the cytosol and 
late endosomes/lysosomes in macrophages. Scale bar is 5 μm.  
 
Figure 4. Flii is not secreted via the classical secretory pathway. A) RAW264.7 
macrophages were immunostained for Flii with VAMP4 (Golgi complex) or TNF, a 
cytokine that traffics through the classical secretory pathway via the Golgi complex. 
Flii did not localise to the Golgi complex or with TNF in the classical secretory 
pathway. Scale bar is 5 μm. B) RAW264.7 macrophages incubated in the presence or 
absence of brefeldin A (BFA) for 60 minutes in the presence of LPS for the final 30 
minutes were fixed and stained for F-actin and the Golgi marker GM130. The Golgi 
complex is disrupted in the presence of BFA. C) Extracts and media from the same 
cells were immunoblotted for Flii. There is no change in the level of Flii secreted in 
the presence of Flii suggesting Flii is not secreted via the classical pathway. 
 
Figure 5. Rab7 and Stx11 regulate the trafficking and secretion of Flii from 
LAMP1 positive late endosomes/lysosomes. A) Extracts and media from 
macrophages transiently transfected with GFP, GFP-Rab7 or GFP-Rab7T22N were 
immunoblotted for Flii, cathepsin D, GFP and actin. Overexpression of wild-type 
Rab7 results in a reduction in intracellular Flii and cathepsin D and a concomitant 
increase in secreted Flii. Conversely, expression of dominant negative form of Rab7 
(Rab7T22N) results in an increase in intracellular Flii and cathepsin D with a 
reduction in secreted Flii. B) Bar graph with SEM shows the fold change in the levels 
of intracellular Flii and cathepsin D and secreted Flii in cells transiently expressing 
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GFP, GFP-Rab7 and GFP-Rab7T22N, calculated from three replicates of immunoblot 
data (**, P<0.01; *, P<0.05). C) Media from RAW264.7 macrophages transiently 
transfected with GFP, GFP-Rab7 or GFP-Rab7T22N was analysed for beta-
hexaminidase activity. Bar graph with SEM shows the activity of beta hexaminidase 
in the media increases when Rab7 is overexpressed and decreases when the dominant 
negative form is expressed (n=3). D) RAW264.7 macrophages were transfected with 
control or Stx11 siRNA. Macrophages were immunstained live on unpermeabilised 
cells for surface LAMP1 then fixed at room temperature. The knockdown of Stx11 
levels results in increased delivery of LAMP1 to the cell surface as previously seen. 
Scale bar is 10 μm. E) Cell extracts and media from macrophages transfected with 
control or Stx11 siRNA were immunblotted for Flii, Stx11 and cathepsin D, along 
with actin as a loading control. Cells depleted of Stx11 have reduced levels of 
intracellular Flii and cathepsin and a concomitant increase in secreted Flii. F) Bar 
chart with SEM shows the reduction in intracellular Flii and cathepsin D in cells 
treated with Stx11 siRNA and the increase in secreted Flii, calculated from three 
replicates of immunoblot data (**, P<0.01; *, P<0.05). G) Media from RAW264.7 
macrophages treated with control or Stx11 siRNA was analysed for beta-
hexaminidase activity. Bar graph with SEM shows the activity of beta hexaminidase 
in the media increases in cells treated with Stx11 siRNA compared to control cells 
(n=3). 
 
Figure 6. Flii forms a complex with LPS and regulates TNF secretion 
A) Schematic representation of the domain structures of Flii showing the two major 
domains: gelsolin and leucine-rich repeat domains. B) NIH3T3 fibroblast conditioned 
media containing LPS (1 μg/ml) was incubated with antibodies (IgGs) to GFP, LPS 
and Flii bound to protein A-agarose. Precipitates were analysed by immunoblotting. 
IP, immuoprecipitated; WCL, whole cell lysate. C) NIH3T3 fibroblast conditioned 
media was pre-incubated in the presence or absence of  antibodies specific to the LRR 
domain of Flii (IgM antibodies, which do not bind protein A-agarose). The media was 
then incubated with LPS and antibodies specific for LPS bound to protein A-agarose 
and precipitates were immoblotted for Flii. Flii is no longer precipitated with LPS in 
the presence of anti-LRR Flii antibodies. IP, immuoprecipitated. D) NIH3T3 
fibroblast conditioned media was pre-incubated in the presence or absence of Flii 
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antibody bound to protein A-agarose and the precipitated proteins discarded. The 
remaining media was immunoblotted for Flii. Flii is depleted from conditioned media 
by antibodies specific for Flii. E) RAW264.7 macrophages grown on coverslips were 
incubated with NIH3T3 fibroblast conditioned media or Flii depleted NIH3T3 
fibroblast conditioned media in the presence of LPS (100 ng/ml) for 3 hours. Cells 
were fixed, permeabilsed and stained for TNF and F-actin. Both the number and level 
of cells containing TNF was increased when Flii is depleted from media. F) Extracts 
from macrophages incubated with NIH3T3 fibroblast conditioned media or Flii 
depleted NIH3T3 fibroblast conditioned media in the presence of LPS (100 ng/ml) for 
3 hours were immunoblotted for TNF and actin. Levels of intracellular TNF are 
increased when Flii is depleted from the media of LPS-stimulated macrophages. 
WCL, whole cell lysate.  G) Media from the same cells was also immunoblotted for 
Flii. Coomassie blue staining of the membrane shows equal loading of proteins. TNF 
secretion is increased from macrophages activated with LPS in the presence of Flii 
depleted media.  H) Bar graph with SEM shows the fold change in both intracellular 
and secreted Flii, calculated from three replicates of immunoblot data (**, P<0.01; *, 
P<0.05).  
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